Ibrahim N Muhsen, Shahrukh K Hashmi, Dietger Niederwieser, Nicolaus Kroeger, Samir Agrawal, Marcelo C Pasquini, Yoshiko Atsuta, Karen K Ballen, Adriana Seber, Wael Saber, Mohamed A Kharfan-Dabaja, Walid Rasheed, Shinichiro Okamoto, Nandita Khera, William A Wood, Mickey B C Koh, Hildegard Greinix, Yoshihisa Kodera, Jeff Szer, Mary M Horowitz, Daniel Weisdorf, Mahmoud Aljurf
Health care costs attributed to biologics have increased exponentially in the recent years, thus biosimilars offer a possible solution to limit costs while maintaining safety and efficacy. Reducing expenditure is vital to health care especially in developing countries where affordability and access to health care is a major challenge. We discuss the opportunities and the challenges of biosimilars in the field of hematopoietic cell transplantation (HCT) in low- and lower-middle income countries. Developing countries can potentially invest in the forecasted costs reduction by utilizing biosimilars...
April 2020: Bone Marrow Transplantation